Johnson & Johnson (JNJ) reported $94.2B in revenue for fiscal 2025, +6.0% year on year. That ranks #45 by revenue among 2853 SEC filers and #10 in Healthcare. Net income was $26.8B, a net margin of 28.5%. Revenue has grown 3.0% a year on average since 2016 ($71.9B then). The fiscal 2025 balance sheet shows $199B in total assets, $19.7B in cash and $39.4B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $94.2B | +6.0% | FY20252025-12-28 |
| Gross profitGrossProfit | $63.9B | +4.2% | FY20252025-12-28 |
| Operating incomeIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $32.6B | +95.2% | FY20252025-12-28 |
| Net incomeNetIncomeLoss | $26.8B | +90.6% | FY20252025-12-28 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $24.5B | +1.1% | FY20252025-12-28 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $4.8B | +9.2% | FY20252025-12-28 |
| Total assetsAssets | $199B | +10.6% | FY20252025-12-28 |
| Shareholders' equityStockholdersEquity | $81.5B | +14.1% | FY20252025-12-28 |
| CashCashAndCashEquivalentsAtCarryingValue | $19.7B | −18.2% | FY20252025-12-28 |
| Long-term debtLongTermDebtNoncurrent | $39.4B | +28.7% | FY20252025-12-28 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-29 | $24.1B | $5.2B | Open → |
| Q2 20262026-06-28 | $25.3B | $5.5B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 13 of 161 companies compared | 28.5% | |
| Operating marginRank 10 of 160 companies compared | 34.6% | |
| R&D as share of revenueRank 99 of 102 companies compared | 0.1% | |
| Cash as share of revenueRank 50 of 160 companies compared | 20.9% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Johnson & Johnson
- Ticker
- JNJ
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 01-03
- CIK
- 0000200406
Filings
- 10-QJul 23, 2026Open filing →
- 10-QApr 22, 2026Open filing →
- 10-KFeb 11, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Elevance HealthELV | $199B | $5.7B |
| CenteneCNC | $195B | −$6.7B |
| HumanaHUM | $130B | $1.2B |
| Johnson & JohnsonJNJ | $94.2B | $26.8B |
| HCA HealthcareHCA | $75.6B | $6.8B |
| Eli LillyLLY | $65.2B | $20.6B |
| MerckMRK | $65.0B | $18.3B |
Johnson & Johnson compared withHCA HealthcareHumana
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Johnson & Johnson — Key figures |url=https://companiesranked.com/en/company/johnson-and-johnson |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Johnson & Johnson — Key figures. CompaniesRanked. https://companiesranked.com/en/company/johnson-and-johnsonBibTeX
@misc{companiesranked-en-company-johnson-and-johnson-2026,
author = {{CompaniesRanked}},
title = {{Johnson \& Johnson — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/johnson-and-johnson}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000200406-26-000016 · February 11, 2026
{{cite web |title=Johnson & Johnson — Key figures — 10-K (0000200406-26-000016) |url=https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.